NO332369B1 - Anvendelse av Lactobacillus casei stammen CNCM I-1518 for fremstilling av et preparat for a forsterke en spesifikk systemisk immunrespons mot et influensa-virus. - Google Patents

Anvendelse av Lactobacillus casei stammen CNCM I-1518 for fremstilling av et preparat for a forsterke en spesifikk systemisk immunrespons mot et influensa-virus. Download PDF

Info

Publication number: NO332369B1
Authority: NO; Norway
Prior art keywords: preparation; group; cells; response; immune response
Prior art date: 2000-05-25

Application number

NO20025595A

Other languages

English (en)

Norwegian (no)

Other versions

NO20025595D0 (no

NO20025595L (no

Inventor

Eric Postaire

Benjamin Bonavida

Original Assignee

Gervais Danone Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-25

Filing date

2002-11-21

Publication date

2012-09-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8850597&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO332369(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-11-21 Application filed by Gervais Danone Sa filed Critical Gervais Danone Sa

2002-11-21 Publication of NO20025595D0 publication Critical patent/NO20025595D0/no

2003-01-22 Publication of NO20025595L publication Critical patent/NO20025595L/no

2012-09-03 Publication of NO332369B1 publication Critical patent/NO332369B1/no

Links

238000002360 preparation method Methods 0.000 title claims abstract description 19
244000199866 Lactobacillus casei Species 0.000 title claims abstract description 15
230000028993 immune response Effects 0.000 title claims description 7
241000712461 unidentified influenza virus Species 0.000 title claims description 7
230000009885 systemic effect Effects 0.000 title claims description 4
LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 title claims 2
235000013958 Lactobacillus casei Nutrition 0.000 title abstract description 6
229940017800 lactobacillus casei Drugs 0.000 title abstract description 6
230000002708 enhancing effect Effects 0.000 title description 2
235000013305 food Nutrition 0.000 claims abstract description 6
235000015872 dietary supplement Nutrition 0.000 claims abstract description 4
235000021001 fermented dairy product Nutrition 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 5
244000000010 microbial pathogen Species 0.000 abstract description 3
230000036039 immunity Effects 0.000 abstract description 2
239000000427 antigen Substances 0.000 description 38
102000036639 antigens Human genes 0.000 description 38
108091007433 antigens Proteins 0.000 description 38
229940068196 placebo Drugs 0.000 description 22
239000000902 placebo Substances 0.000 description 22
230000009696 proliferative response Effects 0.000 description 21
206010022000 influenza Diseases 0.000 description 18
230000000694 effects Effects 0.000 description 16
230000004044 response Effects 0.000 description 13
241000894006 Bacteria Species 0.000 description 12
210000004027 cell Anatomy 0.000 description 12
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
210000001744 T-lymphocyte Anatomy 0.000 description 10
230000035755 proliferation Effects 0.000 description 9
238000004458 analytical method Methods 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
239000008280 blood Substances 0.000 description 8
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 6
241000186660 Lactobacillus Species 0.000 description 6
230000004913 activation Effects 0.000 description 6
235000014655 lactic acid Nutrition 0.000 description 6
239000004310 lactic acid Substances 0.000 description 6
210000000207 lymphocyte subset Anatomy 0.000 description 6
230000000813 microbial effect Effects 0.000 description 6
239000006041 probiotic Substances 0.000 description 6
235000018291 probiotics Nutrition 0.000 description 6
235000013618 yogurt Nutrition 0.000 description 6
241000222120 Candida <Saccharomycetales> Species 0.000 description 5
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 5
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
206010043376 Tetanus Diseases 0.000 description 5
230000036541 health Effects 0.000 description 5
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
239000011550 stock solution Substances 0.000 description 5
210000000662 T-lymphocyte subset Anatomy 0.000 description 4
230000008859 change Effects 0.000 description 4
235000013365 dairy product Nutrition 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
229940039696 lactobacillus Drugs 0.000 description 4
230000000529 probiotic effect Effects 0.000 description 4
241000894007 species Species 0.000 description 4
239000012981 Hank's balanced salt solution Substances 0.000 description 3
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
230000006052 T cell proliferation Effects 0.000 description 3
238000007865 diluting Methods 0.000 description 3
230000003308 immunostimulating effect Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000015788 innate immune response Effects 0.000 description 3
238000005259 measurement Methods 0.000 description 3
244000005700 microbiome Species 0.000 description 3
239000000047 product Substances 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
241000710188 Encephalomyocarditis virus Species 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
235000015140 cultured milk Nutrition 0.000 description 2
238000011161 development Methods 0.000 description 2
238000009826 distribution Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
235000021107 fermented food Nutrition 0.000 description 2
230000037406 food intake Effects 0.000 description 2
230000009610 hypersensitivity Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000008092 positive effect Effects 0.000 description 2
230000037452 priming Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
238000013179 statistical model Methods 0.000 description 2
238000000528 statistical test Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
241000186000 Bifidobacterium Species 0.000 description 1
102100032912 CD44 antigen Human genes 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
241001502567 Chikungunya virus Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
240000001046 Lactobacillus acidophilus Species 0.000 description 1
244000199885 Lactobacillus bulgaricus Species 0.000 description 1
235000004050 Lactobacillus casei DN 114001 Nutrition 0.000 description 1
240000006030 Lactobacillus casei DN 114001 Species 0.000 description 1
241000194036 Lactococcus Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
241000194020 Streptococcus thermophilus Species 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000007503 antigenic stimulation Effects 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
238000004820 blood count Methods 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
230000004706 cardiovascular dysfunction Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
238000009499 grossing Methods 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
229960003971 influenza vaccine Drugs 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
235000020845 low-calorie diet Nutrition 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
230000016379 mucosal immune response Effects 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000004492 positive regulation of T cell proliferation Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000012887 quadratic function Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
230000035899 viability Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/245—Lactobacillus casei

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Mycology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Tropical Medicine & Parasitology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Polymers & Plastics (AREA)
Food Science & Technology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20025595A 2000-05-25 2002-11-21 Anvendelse av Lactobacillus casei stammen CNCM I-1518 for fremstilling av et preparat for a forsterke en spesifikk systemisk immunrespons mot et influensa-virus. NO332369B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0006679A FR2809312B1 (fr)	2000-05-25	2000-05-25	Utilisation de l. casei dans des compositions immunostimulantes
PCT/FR2001/001310 WO2001089541A1 (fr)	2000-05-25	2001-04-27	Utilisation de lactobacillus casei dans des peptides immunostimulantes

Publications (3)

Publication Number	Publication Date
NO20025595D0 NO20025595D0 (no)	2002-11-21
NO20025595L NO20025595L (no)	2003-01-22
NO332369B1 true NO332369B1 (no)	2012-09-03

Family

ID=8850597

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20025595A NO332369B1 (no)	2000-05-25	2002-11-21	Anvendelse av Lactobacillus casei stammen CNCM I-1518 for fremstilling av et preparat for a forsterke en spesifikk systemisk immunrespons mot et influensa-virus.

Country Status (28)

Country	Link
US (1)	US7604809B2 (de)
EP (1)	EP1283714B1 (de)
JP (1)	JP2003534284A (de)
CN (1)	CN1194707C (de)
AR (1)	AR028626A1 (de)
AT (1)	ATE332143T1 (de)
AU (2)	AU5643501A (de)
BG (1)	BG65884B1 (de)
BR (1)	BR0111135A (de)
CA (1)	CA2410350C (de)
CZ (1)	CZ303600B6 (de)
DE (1)	DE60121327T2 (de)
DK (1)	DK1283714T3 (de)
EA (1)	EA005081B1 (de)
ES (1)	ES2267763T3 (de)
FR (1)	FR2809312B1 (de)
HK (1)	HK1055898A1 (de)
HR (1)	HRP20020935A2 (de)
HU (1)	HUP0302041A3 (de)
IL (1)	IL152980A0 (de)
MA (1)	MA25760A1 (de)
MX (1)	MXPA02011636A (de)
NO (1)	NO332369B1 (de)
PL (1)	PL201801B1 (de)
PT (1)	PT1283714E (de)
SK (1)	SK18272002A3 (de)
WO (1)	WO2001089541A1 (de)
ZA (1)	ZA200209087B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6800744B1 (en) *	1997-07-02	2004-10-05	Genome Therapeutics Corporation	Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
GB0009294D0 (en)	2000-04-15	2000-05-31	Sec Dep For The Home Departmen	Improvements in and relating to analysis of DNA samples
US9610347B2 (en) *	2001-04-30	2017-04-04	Cortcontrol	Vaccination response for immunodeficiency or high cortisol
CN1317385C (zh) *	2003-05-30	2007-05-23	上海光明乳业股份有限公司	干酪乳杆菌Bd－II菌株及其在降低血脂方面的应用
US8877178B2 (en)	2003-12-19	2014-11-04	The Iams Company	Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en)	2003-12-19	2005-07-21	The Procter & Gamble Company	Canine probiotic Bifidobacteria pseudolongum
ATE361101T1 (de) *	2004-08-24	2007-05-15	Nutricia Nv	Nahrungszusammensetzung die unverdauliche oligosaccharide enthält
ZA200705844B (en) *	2004-12-15	2008-09-25	Van Der Westhuzen Corne Floris	Detoxifying and immunity-booster composition
EP1683425A1 (de) *	2005-01-21	2006-07-26	Compagnie Gervais Danone	Verwendung von fermentiertem Milchprodukt enthaltend L. Casei zur Herstellung eines Zusammensetzung zur Prävention oder Behandlung Überempfindlichkeitsreaktionen vom verzögerten Typ
ES2264368B1 (es) *	2005-02-11	2007-12-01	Francisco Exposito Mesa	Complemento alimenticio o dietetico compuesto por productos procedentes del lisado de microorganismos.
BRPI0611492B1 (pt)	2005-05-31	2021-10-13	Mars, Incorporated	Bifidobactéria probiótica felina
WO2006130187A1 (en)	2005-05-31	2006-12-07	The Iams Company	Feline probiotic lactobacilli
CA2662226C (en)	2006-09-10	2020-08-04	Glycotope Gmbh	Fully human high yield production system for improved antibodies and proteins
FR2912657B1 (fr) *	2007-02-16	2009-04-17	Gervais Danone Sa	Utilisation de lactobacillus casei pour renforcer la protection induite par la vaccination anti-grippale.
WO2009021585A1 (en) *	2007-08-13	2009-02-19	Dsm Ip Assets B.V.	Probiotic bacteria for rducing the occurence of symptoms of winter infections
WO2009067000A1 (en) *	2007-11-20	2009-05-28	N.V. Nutricia	Composition with synbiotics
EP2119365B1 (de)	2008-05-13	2017-08-16	Glycotope GmbH	Fermentationsprozess
CA2722738C (en) *	2008-05-13	2017-04-25	Glycotope Gmbh	Fermentation process
US9771199B2 (en)	2008-07-07	2017-09-26	Mars, Incorporated	Probiotic supplement, process for making, and packaging
EP2153837A1 (de)	2008-08-14	2010-02-17	Compagnie Gervais Danone	Zusammensetzungen mit Lactobacillus casei zur Verbesserung der Resistenz gegen verbreitete Infektionskrankheiten
FR2937252B1 (fr) *	2008-10-17	2011-05-20	Pf Medicament	Association d'un extrait de sureau et d'une souche de l. paracasei.
US10104903B2 (en)	2009-07-31	2018-10-23	Mars, Incorporated	Animal food and its appearance
BR112012016894A2 (pt) *	2010-01-08	2015-09-15	Gervais Danone Sa	lactobacilos com ação antioxidante.
EA031179B1 (ru) *	2010-03-12	2018-11-30	Компани Жервэ Данон	Молочнокислые бактерии, применяемые при чревной болезни
CN105288616B (zh) *	2010-10-15	2018-10-19	科.汉森有限公司	免疫佐剂
EP2455092A1 (de)	2010-11-11	2012-05-23	Nestec S.A.	Nicht replizierende probiotische Mikroorganismen als Schutz vor Infektionen der oberen Atemwege
US9700610B2 (en)	2011-08-22	2017-07-11	Glycotope Gmbh	Microorganisms carrying a tumor antigen
WO2014038929A1 (en)	2012-09-07	2014-03-13	N.V. Nutricia	Probiotics for producing antiviral factors
CA3100608A1 (en)	2018-05-18	2019-11-21	Daiichi Sankyo Co., Ltd.	Anti-muc1 antibody-drug conjugate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH05236872A (ja) *	1992-02-27	1993-09-17	Takanashi Nyugyo Kk	乳酸菌含有食品
JP4112021B2 (ja) *	1994-02-16	2008-07-02	明治乳業株式会社	乳酸菌を用いた免疫賦活剤
WO1996020607A1 (fr) *	1995-01-02	1996-07-11	Compagnie Gervais Danone	Ferment lactique, et son utilisation pour la preparation de produits anti-diarrheiques
CN1150314C (zh) *	1997-08-21	2004-05-19	纽西兰乳品局	增强免疫的乳酸菌
US6699517B2 (en) *	1997-11-28	2004-03-02	Compagnie Gervais Danone	Method for preparing food products by fermenting soy milk with streptococcus thermophilus
IT1298918B1 (it) *	1998-02-20	2000-02-07	Mendes Srl	Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
KR100324441B1 (ko) *	1999-02-08	2002-02-27	이은선	위염, 위궤양, 십이지장궤양 예방을 위한 식품

2000
- 2000-05-25 FR FR0006679A patent/FR2809312B1/fr not_active Expired - Fee Related
2001
- 2001-04-27 HU HU0302041A patent/HUP0302041A3/hu unknown
- 2001-04-27 SK SK1827-2002A patent/SK18272002A3/sk not_active Application Discontinuation
- 2001-04-27 AU AU5643501A patent/AU5643501A/xx active Pending
- 2001-04-27 MX MXPA02011636A patent/MXPA02011636A/es active IP Right Grant
- 2001-04-27 JP JP2001585785A patent/JP2003534284A/ja active Pending
- 2001-04-27 BR BR0111135-3A patent/BR0111135A/pt not_active IP Right Cessation
- 2001-04-27 PT PT01929743T patent/PT1283714E/pt unknown
- 2001-04-27 EP EP01929743A patent/EP1283714B1/de not_active Expired - Lifetime
- 2001-04-27 AT AT01929743T patent/ATE332143T1/de active
- 2001-04-27 DK DK01929743T patent/DK1283714T3/da active
- 2001-04-27 CA CA2410350A patent/CA2410350C/fr not_active Expired - Lifetime
- 2001-04-27 CN CNB018100511A patent/CN1194707C/zh not_active Expired - Fee Related
- 2001-04-27 US US10/276,315 patent/US7604809B2/en not_active Expired - Fee Related
- 2001-04-27 WO PCT/FR2001/001310 patent/WO2001089541A1/fr active IP Right Grant
- 2001-04-27 AU AU2001256435A patent/AU2001256435B2/en not_active Ceased
- 2001-04-27 ES ES01929743T patent/ES2267763T3/es not_active Expired - Lifetime
- 2001-04-27 IL IL15298001A patent/IL152980A0/xx unknown
- 2001-04-27 CZ CZ20024189A patent/CZ303600B6/cs unknown
- 2001-04-27 PL PL358408A patent/PL201801B1/pl unknown
- 2001-04-27 EA EA200201248A patent/EA005081B1/ru not_active IP Right Cessation
- 2001-04-27 DE DE60121327T patent/DE60121327T2/de not_active Expired - Lifetime
- 2001-05-24 AR ARP010102498A patent/AR028626A1/es unknown
2002
- 2002-11-08 ZA ZA200209087A patent/ZA200209087B/xx unknown
- 2002-11-20 BG BG107299A patent/BG65884B1/bg unknown
- 2002-11-21 NO NO20025595A patent/NO332369B1/no not_active IP Right Cessation
- 2002-11-25 HR HR20020935A patent/HRP20020935A2/hr not_active Application Discontinuation
- 2002-12-20 MA MA26968A patent/MA25760A1/fr unknown
2003
- 2003-11-12 HK HK03108188A patent/HK1055898A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
NO20025595D0 (no)	2002-11-21
FR2809312B1 (fr)	2002-07-12
EP1283714A1 (de)	2003-02-19
IL152980A0 (en)	2003-06-24
AR028626A1 (es)	2003-05-14
HUP0302041A2 (hu)	2003-09-29
BG107299A (bg)	2003-07-31
CN1194707C (zh)	2005-03-30
CA2410350A1 (fr)	2001-11-29
CZ20024189A3 (cs)	2003-05-14
DE60121327T2 (de)	2007-07-26
HK1055898A1 (en)	2004-01-30
JP2003534284A (ja)	2003-11-18
US7604809B2 (en)	2009-10-20
CZ303600B6 (cs)	2013-01-02
PL201801B1 (pl)	2009-05-29
AU2001256435B2 (en)	2006-06-29
SK18272002A3 (sk)	2003-08-05
HRP20020935A2 (en)	2005-02-28
PL358408A1 (en)	2004-08-09
CA2410350C (fr)	2013-04-09
DE60121327D1 (de)	2006-08-17
HUP0302041A3 (en)	2005-11-28
MA25760A1 (fr)	2003-04-01
NO20025595L (no)	2003-01-22
DK1283714T3 (da)	2006-10-30
CN1430518A (zh)	2003-07-16
EP1283714B1 (de)	2006-07-05
ZA200209087B (en)	2004-06-30
EA200201248A1 (ru)	2003-06-26
FR2809312A1 (fr)	2001-11-30
ATE332143T1 (de)	2006-07-15
ES2267763T3 (es)	2007-03-16
BG65884B1 (bg)	2010-04-30
BR0111135A (pt)	2003-04-08
AU5643501A (en)	2001-12-03
US20040029127A1 (en)	2004-02-12
WO2001089541A1 (fr)	2001-11-29
EA005081B1 (ru)	2004-10-28
PT1283714E (pt)	2006-11-30
MXPA02011636A (es)	2003-05-14

Legal Events

Date	Code	Title	Description
2016-11-28	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO332369B1 (no)	2012-09-03	Anvendelse av Lactobacillus casei stammen CNCM I-1518 for fremstilling av et preparat for a forsterke en spesifikk systemisk immunrespons mot et influensa-virus.
Pedersen et al.	2012	Biodiversity and probiotic potential of yeasts isolated from Fura, a West African spontaneously fermented cereal
Sheikh et al.	2010	Zinc influences innate immune responses in children with enterotoxigenic Escherichia coli-induced diarrhea
US9314041B2 (en)	2016-04-19	Immune function modulating agents
DK2734049T3 (en)	2018-07-30	PROBIOTIC COMPOSITIONS AND PROCEDURES
Bolton et al.	2008	Probiotics: potential to prevent HIV and sexually transmitted infections in women
JP5511649B2 (ja)	2014-06-04	免疫調節製剤としてのラクトバチルス・パラカゼイｌｔ１２株
US11260085B2 (en)	2022-03-01	Salt-tolerant lactobacillus, method of culturing salt-tolerant lactobacillus, and immunostimulant
Zacarías et al.	2014	Mortality and translocation assay to study the protective capacity of Bifidobacterium lactis INL1 against Salmonella Typhimurium infection in mice
Vissers et al.	2011	Lactobacillus strains differentially modulate cytokine production by hPBMC from pollen-allergic patients
EP2627198A1 (de)	2013-08-21	Immunadjuvans
WO2009068474A1 (en)	2009-06-04	Strains of lactobacillus plantarum as probiotics with immunomodulatory specific effect
AboNahas et al.	2022	Trust your gut: the human gut microbiome in health and disease
US8349315B2 (en)	2013-01-08	Use of Lactobacillus casei for increasing the protection provided by the influenza vaccine
Fujiwara et al.	2005	A double-blind trial of Lactobacillus paracasei strain KW3110 administration for immunomodulation in patients with pollen allergy
Shetty et al.	2014	A study to find the status of probiotics in New Delhi, India and review of strains of bacteria used as probiotics
US20230146454A1 (en)	2023-05-11	Lactobacillus reuteri
El-Bakry et al.	2013	Role of some selected Bifidobacterium strains in modulating immunosenescence of aged albino rats
CN114269897B (zh)	2024-08-02	罗伊乳杆菌
EP3798322B1 (de)	2022-12-21	Lactobacillus reuteri